• Publications
  • Influence
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate theExpand
  • 849
  • 57
  • PDF
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
PURPOSE Trebananib, a peptibody that blocks binding of angiopoietin-1 and -2 to Tie2, significantly prolonged progression-free survival (PFS) in patients with recurrent epithelial ovarian cancer inExpand
  • 49
  • 2
Anti-Angiopoietin Therapy With Trebananib for Recurrent Ovarian Cancer (TRINOVA-1): A Randomised, Multicentre, Double-blind, Placebo-Controlled Phase 3 Trial
Author(s): Monk, BJ; Poveda, A; Vergote, I; Raspagliesi, F; Fujiwara, K; Bae, DS; Oaknin, A; Ray-Coquard, I; Provencher, DM; Karlan, BY; Lhomme, C; Richardson, G; Rincon, DG; Coleman, RL; Herzog, TJ;Expand
  • 55
  • 2
Gemcitabine and docetaxel as front‐line chemotherapy in patients with carcinoma of an unknown primary site
The current study was performed to evaluate the efficacy and toxicity of a noncisplatin‐based chemotherapy regimen combining gemcitabine and docetaxel as front‐line chemotherapy for patients withExpand
  • 51
  • 1
Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
Abstract Lessons Learned. Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderlyExpand
  • 12
  • 1
  • PDF
Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile: A Phase 2 Trial
Objective Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance proteinExpand
  • 32
  • 1
Heterogeneity in the geographic distribution of diffuse grade II and III gliomas in France.
2067 Background: Diffuse WHO grade II and III gliomas (DGII/IIIG) are rare tumors (incidence ≤ 2/105person-years). Specific epidemiological studies are very rare. The main objective of this work is...
  • 1
Attentes des patientes suivies pour un cancer de l’ovaire concernant les traitements d’entretien : résultats de la cohorte française GINECO de l’enquête européenne NOGGO/ENGOT-ov22 (Expression IV)
Resume Introduction Expression IV est une enquete europeenne evaluant les attentes des patientes suivies pour un cancer de l’ovaire concernant les traitements d’entretien. Methode Quatre cent uneExpand
  • 2
Stability of the principal cytostatic agents during storage at unusual temperatures
Abstract The aim of our study was to determine the stability of ten antineoplastic drugs stored in their initial package, in conditions of temperature which may be encountered during transport toExpand
  • 2